U.S. Health and Human Services Secretary Robert F. Kennedy Jr. announced a bold plan to identify the cause of autism by September 2025. Speaking at a cabinet meeting with President Donald Trump, Kennedy declared a global research initiative involving hundreds of scientists to determine the source of rising autism rates, which reached 1 in 36 children by 2020, according to the CDC.
“We’ll know by September what has caused the autism epidemic and how to eliminate those exposures,” Kennedy said, hinting at environmental and artificial factors. The initiative is part of Trump’s broader “Make America Healthy Again” Commission, which is also reviewing rising childhood conditions like asthma and ADHD.
The autism community, however, responded with skepticism. Kristyn Roth of the Autism Society of America criticized the deadline and the framing of autism as an “epidemic,” warning it promotes fear and stigmatization. Experts caution that increased diagnoses are largely due to expanded diagnostic criteria and awareness, not an unknown epidemic.
Kennedy, known for promoting a disproven link between vaccines and autism, confirmed vaccines will be reviewed, along with potential environmental and lifestyle triggers. Meanwhile, a recent study has strengthened ties between prenatal diabetes and autism risk.
Controversy deepened after reports surfaced of David Geier—previously fined for unlicensed medical practices—being hired to investigate vaccine links. Lawmakers and advocacy groups fear the spread of misinformation under Kennedy’s leadership.
The National Institutes of Health and the CDC, both under Kennedy’s purview, are planning multimillion-dollar research efforts into autism causes, including vaccine-related studies. Critics argue the push may politicize science and mislead the public.
Despite widespread concern, Kennedy remains firm: “There will be no bigger news than finding the cause of autism.” Whether science can meet his deadline remains uncertain.


Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine
Moderna to Pay Up to $2.25B to Settle LNP Patent Dispute Over COVID-19 Vaccine Technology
U.S. Officials Express Optimism Over New CDC Director Selection Amid Vaccine Policy Turmoil
Trump Administration Seeks Court Pause to Reinstate 10% Global Tariffs
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Blue Origin’s New Glenn Achieves Breakthrough Success With First NASA Mission
SpaceX’s Starship Completes 11th Test Flight, Paving Way for Moon and Mars Missions
Malaysia Unveils Energy Security Plan Amid Iran Conflict and Rising Oil Costs
Trump Signs Executive Order to Boost AI Research in Childhood Cancer
EU Approves New Sanctions on Israeli Settlers and Hamas Leaders
NASA's Artemis II Crew Arrives in Florida for Historic Moon Mission
Arcadia Mayor Eileen Wang Pleads Guilty in China Foreign Agent Case
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage
CDC Acting Director Urges Measles Vaccination as U.S. Cases Surge in 2026
Tabletop particle accelerator could transform medicine and materials science
US, Japan Reaffirm Strong Currency Coordination Amid Yen Volatility
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment 



